두경부암에서 항암치료의 전망과 이슈

키워드

참고문헌 (25)

1. Jemal A, "Global cancer statistics", CA Cancer J Clin, 61(2), pp.69~90 (2011)
2. Forastiere A, "Head and neck cancer", N Engl J Med, 345(26), pp.1890~1900 (2001)
3. Carvalho AL, "Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database", Int J Cancer, 114(5), pp.806~816 (2005)
4. Wu TT, "Nanoparticle-based targeted therapeutics in head-and-neck cancer", Int J Med Sci, 12(2), pp.187~200 (2015)
5. Friedman JM, "Clinical and scientific impact of human papillomavirus on head and neck cancer", World J Clin Oncol, 5(4), pp.781~791 (2014)
6. Das LC, "Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades", Ann Oncol, 26(1), pp.198~205 (2015)
7. Sethi S, "Characteristics and survival of head and neck cancer by HPV status: a cancer registry-based study", Int J Cancer, 131(5), pp.1179~1186 (2012)
8. Mirghani H, "Increased radiosensitivity of HPV-positive head and neck cancers:Molecular basis and therapeutic perspectives", Cancer Treat Rev, 41(10), pp.844~852 (2015)
9. Urban D, "What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?", Cancer, 120(10), pp.1462~1470 (2014)
10. Kalyankrishna S, "Epidermal growth factor receptor biology in head and neck cancer", J Clin Oncol, 24(17), pp.2666~2672 (2006)
11. Psyrri A, "Molecular pathways in head and neck cancer: EGFR, PI3K, and more", Am Soc Clin Oncol Educ Book, 2013, pp.246~255 (2013)
12. "J Clin Oncol", 2009, 1864~1871
13. Suh Y, "Clinical update on cancer: molecular oncology of head and neck cancer", Cell Death Dis, 5, pp.e1018~ (2014)
14. Agrawal N, "Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1", Science, 333(6046), pp.1154~1157 (2011)
15. Sun W, "Activation of the NOTCH pathway in head and neck cancer", Cancer Res, 74(4), pp.1091~1104 (2014)
16. Munn DH, "Immune suppressive mechanisms in the tumor microenvironment", Curr Opin Immunol, 39, pp.1~6 (2016)
17. Topalian SL, "Immune checkpoint blockade: a common denominator approach to cancer therapy", Cancer Cell, 27(4), pp.450~461 (2015)
18. Badoual C, "Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer", Cancer Res, 73(1), pp.128~138 (2013)
19. Kono K, "Current status of cancer immunotherapy", J Stem Cells Regen Med, 10(1), pp.8~13 (2014)
20. Cecco S, "Cancer vaccines in phase II", III clinical trials: state of the art and future perspectives, 2011, pp.11(1), 85~102
21. Voskens CJ, "Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma", Head Neck, 34(12), pp.1734~1746 (2012)
22. Steinman RM, "Taking dendritic cells into medicine", Nature, 449(7161), pp.419~426 (2007)
23. Palucka K, "Cancer immunotherapy via dendritic cells", Nat Rev Cancer, 12(4), pp.265~277 (2012)
24. Ma Y, "Dendritic cells in the cancer microenvironment", J Cancer, 4(1), pp.36~44 (2013)
25. Ferris RL, "Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck", N Engl J Med (2016)

관련 논문AI추천